Cargando…

Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis

Viral infections cause many severe human diseases, being responsible for remarkably high mortality rates. In this sense, both the academy and the pharmaceutical industry are continuously searching for new compounds with antiviral activity, and in addition, face the challenge of developing greener an...

Descripción completa

Detalles Bibliográficos
Autores principales: da Silva, Everton M., Vidal, Hérika D. A., Corrêa, Arlene G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625736/
https://www.ncbi.nlm.nih.gov/pubmed/34832907
http://dx.doi.org/10.3390/ph14111125
_version_ 1784606494554062848
author da Silva, Everton M.
Vidal, Hérika D. A.
Corrêa, Arlene G.
author_facet da Silva, Everton M.
Vidal, Hérika D. A.
Corrêa, Arlene G.
author_sort da Silva, Everton M.
collection PubMed
description Viral infections cause many severe human diseases, being responsible for remarkably high mortality rates. In this sense, both the academy and the pharmaceutical industry are continuously searching for new compounds with antiviral activity, and in addition, face the challenge of developing greener and more efficient methods to synthesize these compounds. This becomes even more important with drugs possessing stereogenic centers as highly enantioselective processes are required. In this minireview, the advances achieved to improve synthetic routes efficiency and sustainability of important commercially antiviral chiral drugs are discussed, highlighting the use of organocatalytic methods.
format Online
Article
Text
id pubmed-8625736
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86257362021-11-27 Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis da Silva, Everton M. Vidal, Hérika D. A. Corrêa, Arlene G. Pharmaceuticals (Basel) Review Viral infections cause many severe human diseases, being responsible for remarkably high mortality rates. In this sense, both the academy and the pharmaceutical industry are continuously searching for new compounds with antiviral activity, and in addition, face the challenge of developing greener and more efficient methods to synthesize these compounds. This becomes even more important with drugs possessing stereogenic centers as highly enantioselective processes are required. In this minireview, the advances achieved to improve synthetic routes efficiency and sustainability of important commercially antiviral chiral drugs are discussed, highlighting the use of organocatalytic methods. MDPI 2021-11-04 /pmc/articles/PMC8625736/ /pubmed/34832907 http://dx.doi.org/10.3390/ph14111125 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
da Silva, Everton M.
Vidal, Hérika D. A.
Corrêa, Arlene G.
Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis
title Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis
title_full Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis
title_fullStr Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis
title_full_unstemmed Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis
title_short Advances on Greener Asymmetric Synthesis of Antiviral Drugs via Organocatalysis
title_sort advances on greener asymmetric synthesis of antiviral drugs via organocatalysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625736/
https://www.ncbi.nlm.nih.gov/pubmed/34832907
http://dx.doi.org/10.3390/ph14111125
work_keys_str_mv AT dasilvaevertonm advancesongreenerasymmetricsynthesisofantiviraldrugsviaorganocatalysis
AT vidalherikada advancesongreenerasymmetricsynthesisofantiviraldrugsviaorganocatalysis
AT correaarleneg advancesongreenerasymmetricsynthesisofantiviraldrugsviaorganocatalysis